These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36020)

  • 1. Advances in the neuropharmacology of Parkinsonism.
    Calne DB; Kebabian J; Silbergeld E; Evarts E
    Ann Intern Med; 1979 Feb; 90(2):219-29. PubMed ID: 36020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in the pharmacology and therapeutics of parkinsonism.
    Calne DB
    Ann Neurol; 1977 Feb; 1(2):111-9. PubMed ID: 18978
    [No Abstract]   [Full Text] [Related]  

  • 3. [Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease].
    Brücke T; Riederer P
    Wien Med Wochenschr; 1986 Aug; 136(15-16):401-8. PubMed ID: 2878540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Problems and future perspectives in the treatment of Parkinson's disease].
    Hens L; Hellemans J
    Tijdschr Gerontol Geriatr; 1982 Aug; 13(4):147-54. PubMed ID: 6127822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems.
    Brichta L; Greengard P; Flajolet M
    Trends Neurosci; 2013 Sep; 36(9):543-54. PubMed ID: 23876424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional alpha-synuclein aggregation, dopaminergic dysregulation, and the development of drug-related visual hallucinations in Parkinson's disease.
    Papapetropoulos S
    J Neuropsychiatry Clin Neurosci; 2006; 18(2):149-57. PubMed ID: 16720791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GABA receptor agonists and extrapyramidal motor function: therapeutic implications for Parkinson's disease.
    Bartholini G; Scatton B; Zivkovic B; Lloyd KG
    Adv Neurol; 1987; 45():79-83. PubMed ID: 3030072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medicamentous strategy for improving the quality of life in the senescence].
    Knoll J
    Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of dopaminergic agents in Parkinson's disease.
    Koller WC; Rueda MG
    Neurology; 1998 Jun; 50(6 Suppl 6):S11-4; discussion S44-8. PubMed ID: 9633680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinsonism: candidate disorder for implanted pumps?
    Nutt JG
    Ann N Y Acad Sci; 1988; 531():194-9. PubMed ID: 2898229
    [No Abstract]   [Full Text] [Related]  

  • 12. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The treatment of Parkinson's disease--adenosine A2A receptor antagonists].
    Matsubara E; Shoji M; Abe K
    Nihon Rinsho; 2002 Jan; 60(1):112-6. PubMed ID: 11808320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biochemistry of neuronal transmission. Pharmacology of parkinsonism].
    Lombardo L
    Gac Med Mex; 1981 Dec; 117(12):476-8. PubMed ID: 6123462
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacotherapy of Parkinson's disease.
    Cohen MM; Scheife RT
    Am J Hosp Pharm; 1977 May; 34(5):531-8. PubMed ID: 326045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy.
    Grace AA
    Mov Disord; 2008; 23 Suppl 3():S560-9. PubMed ID: 18781673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
    Youdim MB; Riederer PF
    Neurology; 2004 Oct; 63(7 Suppl 2):S32-5. PubMed ID: 15477584
    [No Abstract]   [Full Text] [Related]  

  • 19. Dopamine receptor agonists in the treatment of advanced Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S54-7. PubMed ID: 20123558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.